Establishing the market-readiness of an in vivo technology for assessing drug toxicity-induced tissue damage
Ended Project Grant Awarded Last action
- Award ID
- R41GM140538
- Recipient
-
Durametrix LLC UEI KACSQ7VNS1L7
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $771,525
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date
- Funding
-
- $514,350.00 Federal
- $257,175.00 Non-federal
- Place of performance
- Oak Creek, WI 53154, USA
Award details come from USAspending.gov.
Description
- Abstract
- In drug r & d IT is critical to be able to understand toxicity and to identify and eliminate overly toxic candidates. However, there is a significant technological GAP for in vivo toxicity testing. To address this challenge, we developed a novel imaging-based approach that detects toxicity-induced tissue injury in a minimally invasive, whole body and dynamic fashion. The invention and development of the technology has had a substantial academic track record by our scientists; and its commercialization is driven by a strong market need, technical expertise and marketing know-how. The goal of the current phase i sttr grant is twofold: 1) to determine the sensitivity and specificity of our imaging technology, and 2) to establish a user-friendly report system which summarizes and presents the findings to end users who have a general drug r & d background. The accomplishment of our goal will enable US to launch a market-ready service package with user accessibility. Overall, this in vivo imaging approach identifies an important marker for drug toxicity on a personalized basis with an objective and quantitative metric. The early detection of drug toxicity in susceptible tissues will help make timely decisions in drug r & d by prioritizing safe and efficacious candidates.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $257,175 | $0 | |
| Original award | $257,175 | $257,175 |
Quick answers
Who received award R41GM140538?
R41GM140538 was awarded to Durametrix LLC by National Institute of General Medical Sciences (National Institutes of Health) on February 2, 2021.
How much is award R41GM140538 worth?
$771,525 has been obligated on R41GM140538: $514,350 in federal funding and $257,175 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award